A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
Status:
Completed
Trial end date:
2016-08-25
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to evaluate the impact of UX007 on acute clinical
pathophysiology associated with LC-FAOD following 24 weeks of treatment.